IDNA vs. XBI
IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) and XBI (SPDR S&P Biotech ETF) are both Health & Biotech Equities funds - IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index while XBI tracks the S&P Biotechnology Select Industry Index. Both are passively managed. Over the past 5 years, IDNA returned -8.26%/yr vs 0.26%/yr for XBI. Their correlation of 0.91 suggests significant overlap in exposure. IDNA charges 0.47%/yr vs 0.35%/yr for XBI.
Performance
IDNA vs. XBI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IDNA achieves a 9.51% return, which is significantly higher than XBI's 4.78% return.
IDNA
- 1D
- -2.18%
- 1M
- -2.18%
- YTD
- 9.51%
- 6M
- 10.53%
- 1Y
- 41.74%
- 3Y*
- 6.48%
- 5Y*
- -8.26%
- 10Y*
- —
XBI
- 1D
- -4.39%
- 1M
- -2.04%
- YTD
- 4.78%
- 6M
- 8.21%
- 1Y
- 57.84%
- 3Y*
- 14.12%
- 5Y*
- 0.26%
- 10Y*
- 8.35%
IDNA vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 9.51% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
XBI SPDR S&P Biotech ETF | 4.78% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 14.57% |
Correlation
The correlation between IDNA and XBI is 0.90, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.90 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.90 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.90 |
Correlation (All Time) Calculated using the full available price history since Jun 14, 2019 | 0.91 |
The correlation between IDNA and XBI has been stable across timeframes, ranging from 0.90 to 0.91 - a consistent structural relationship.
IDNA vs. XBI - Sectors Allocation Comparison
Sectors
IDNA
XBI
Healthcare
Industrials
-
Basic Materials
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
IDNA
XBI
Industrials
IDNA
XBI
-
Basic Materials
IDNA
-
XBI
Communication Services
IDNA
-
XBI
-
Consumer Cyclical
IDNA
-
XBI
-
Consumer Defensive
IDNA
-
XBI
-
Energy
IDNA
-
XBI
-
Financial Services
IDNA
-
XBI
Real Estate
IDNA
-
XBI
-
Technology
IDNA
-
XBI
-
Utilities
IDNA
-
XBI
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IDNA vs. XBI — Risk / Return Rank
IDNA
XBI
IDNA vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IDNA | XBI | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.71 | 2.28 | -0.57 |
Sortino ratioReturn per unit of downside risk | 2.48 | 3.14 | -0.66 |
Omega ratioGain probability vs. loss probability | 1.28 | 1.37 | -0.09 |
Calmar ratioReturn relative to maximum drawdown | 4.09 | 6.37 | -2.28 |
Martin ratioReturn relative to average drawdown | 11.79 | 19.55 | -7.76 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IDNA | XBI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.71 | 2.28 | -0.57 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.29 | 0.01 | -0.30 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.26 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.10 | 0.36 | -0.26 |
Drawdowns
IDNA vs. XBI - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for IDNA and XBI.
Loading charts...
Drawdown Indicators
| IDNA | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.26% | -63.89% | -4.37% |
Max Drawdown (1Y)Largest decline over 1 year | -10.66% | -9.72% | -0.94% |
Max Drawdown (3Y)Largest decline over 3 years | -29.73% | -32.99% | +3.26% |
Max Drawdown (5Y)Largest decline over 5 years | -68.26% | -54.71% | -13.55% |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.89% | — |
Current DrawdownCurrent decline from peak | -46.01% | -26.16% | -19.85% |
Average DrawdownAverage peak-to-trough decline | -36.24% | -20.93% | -15.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.70% | 3.17% | +0.53% |
Volatility
IDNA vs. XBI - Volatility Comparison
The current volatility for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) is 7.24%, while SPDR S&P Biotech ETF (XBI) has a volatility of 9.43%. This indicates that IDNA experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IDNA | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.24% | 9.43% | -2.19% |
Volatility (6M)Calculated over the trailing 6-month period | 18.21% | 20.31% | -2.10% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.51% | 25.57% | -1.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.42% | 32.17% | -3.75% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.53% | 32.00% | -2.47% |
IDNA vs. XBI - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is higher than XBI's 0.35% expense ratio.
Dividends
IDNA vs. XBI - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 1.08%, more than XBI's 0.34% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.08% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Frequently Asked Questions
IDNA and XBI have a correlation of 0.90, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
XBI has higher volatility (9.43%) compared to IDNA (7.24%). In terms of maximum drawdown, IDNA dropped -68.26% vs XBI's -63.89%.
On 5-year performance, XBI leads with 0.26% vs -8.26% for IDNA. On fees, XBI is cheaper at 0.35% per year. On volatility, IDNA has been the lower-risk option at 7.24%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, XBI has performed better with a 0.26% return vs -8.26%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XBI is cheaper with a 0.35% expense ratio, compared with 0.47% for IDNA.
IDNA has the higher dividend yield at 1.08%, compared with 0.34% for XBI.
IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index, while XBI tracks S&P Biotechnology Select Industry Index. They also come from different issuers: iShares and State Street. Their fees differ too: 0.47% for IDNA and 0.35% for XBI.
XBI currently has the higher Sharpe Ratio (2.28 vs 1.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IDNA and XBI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer